Endothelial function improves within 6 weeks of treatment with methotrexate or methotrexate in combination with a TNF-α inhibitor in rheumatoid arthritis patients

Scandinavian Journal of Rheumatology

Volumn 41, Issue 3, 2012, Pages 240-242

  Hjeltnes, G ^a   Hollan, I ^a   Forre, O ^b   Wiik, A ^c   Lyberg, T ^b   Mikkelsen, K ^a   Agewall, S ^b  

^a Hospital for Rheumatic Diseases   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c STATENS SERUM INSTITUT   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; IMMUNOGLOBULIN M; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METHOTREXATE; RHEUMATOID FACTOR; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ADULT; ATHEROSCLEROSIS; BODY MASS; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE DURATION; ENDOTHELIAL DYSFUNCTION; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FOLLOW UP; HUMAN; LETTER; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PLETHYSMOGRAPH; PRIORITY JOURNAL; PROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; TREATMENT DURATION; TREATMENT OUTCOME;

AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DRUG THERAPY, COMBINATION; ENDOTHELIUM, VASCULAR; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; PLETHYSMOGRAPHY; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84860592437     PISSN: 03009742     EISSN: 15027732     Source Type: Journal    
DOI: 10.3109/03009742.2012.656698     Document Type: Letter

References (8)

1. Gabriel SE. Cardiovascular morbidity and mortality in rheumatoid arthritis. Am J Med 2008;121:9-14.
2. Rubinshtein R, Kuvin JT, Soffler M, Lennon RJ, Lavi S, Nelson RE, et al. Assessment of endothelial function by non-invasive peripheral arterial tonometry predicts late cardiovascular adverse events. Eur Heart J 2010;31:1142-8.
3. Bonetti PO, Pumper GM, Higano ST, Holmes DR Jr, Kuvin JT, Lerman A. Non-invasive identification of patients with early coronary atherosclerosis by assessment of digital reactive hyperemia. J Am Coll Cardiol 2004;44:2137-41. (Pubitemid 39576032)
4. Kahn F, Galarraga B, Belch JJ. The role of endothelial function and its assessment in rheumatoid arthritis. Nat Rev Rheumatol 2010; 6:253-61.
5. Hjeltnes G, Hollan I, Forre O, Wiik A, Mikkelsen K, Agewall S. Anti-CCP and RF IgM: Predictors of impaired endothelial function in RA patients. Scand J Rheumatol 2011;40:422-7.
6. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1984;27:361-8.
7. Swierkot J, Szechinski J. Methotrexate in rheumatoid arthritis. Pharmacol Rep 2006;58:473-92. (Pubitemid 44383273)
8. Hollan I, Scott H, Saatvedt K, Prayson R, Mikkelsen K, Nossent HC, et al. Inflammatory rheumatic disease and smoking are predictors of aortic inflammation: A controlled study of biopsy specimens obtained at coronary artery surgery. Arthritis Rheum 2007;56:2072-9. (Pubitemid 47110407)